Abstract
Overview
Introduction
The market for antifungals is shifting. Sales of old market leade, Pfizer' s
diflucan, have been eroded by generics, and a clear new market leader has yet
to emerge. Relatively new drugs within the azole and the candin class are
battling for supremacy, while entirely new approaches in the pipeline may have
the potential to change the landscape yet again.
View Cart
